NUS and 22Health Ventures Launch Digital Health Accelerator DATA with $50,000 Grant for Selected Startups

Recently, the National University of Singapore’s Yong Loo Lin School of Medicine and early-stage healthcare technology investment firm 22Health Ventures announced a joint initiative to establish the NUS Digital Health Advanced Technology Accelerator (DATA), aimed at empowering digital health startups in Singapore and Southeast Asia.

The National University of Singapore’s Medical Digital Advanced Technology Accelerator (DATA) focuses on “fostering digital healthcare concepts.” By partnering with leading clinical experts and business leaders in the industry, and leveraging an 11-week innovation accelerator program, DATA provides digital health startups with entrepreneurial services such as global industry resource matching, capital empowerment, market validation, and expedited regulatory approval pathways through startup competitions, diverse conferences, and business courses. Selected companies will also receive USD 50,000 (approximately RMB 350,000) in seed funding.

Established in 1905, the Yong Loo Lin School of Medicine at the National University of Singapore is the first and largest medical school in Singapore. In 2005, to mark its centennial anniversary, the school received a S$100 million donation from the Tan Chin Tuan Foundation. In recognition of this philanthropic contribution, the NUS Faculty of Medicine was renamed the NUS Yong Loo Lin School of Medicine.

The Yong Loo Lin School of Medicine at the National University of Singapore is a leading medical research institution in Asia, conducting in-depth and innovative research in fields such as regenerative medicine, digital health, and cancer science.

On July 19, *Nature Medicine* published a study in which Professor Tan Yuzong’s team at the National University of Singapore, in collaboration with Tsinghua University and Shanghai Jiao Tong University, developed an integrated vision–large language model system for diabetes diagnosis and treatment. By combining large language models with deep learning techniques based on fundus images, the system provides primary care physicians with personalized diabetes management recommendations and assisted diagnostic results for diabetic retinopathy. The findings indicate that this system holds promise for significantly improving primary diabetes care and diabetic retinopathy (DR) screening in low- and middle-income countries.

The Yong Loo Lin School of Medicine at the National University of Singapore covers virtually all medical disciplines and has established multiple institutes and research centers, such as the Behavioural and Implementation Science Interventions (BISI) Centre, the Centre for Biomedical Ethics (CbME), the Memory, Ageing and Cognition Centre (MACC), and the Global Asian Women’s Health Centre. Among these, CbME is one of the largest academic research centers for bioethics in Asia, encompassing clinical, health systems, and public health ethics, as well as the ethics and regulation of emerging sciences and biomedical technologies.

These research efforts have not only advanced medical science but also provided a rich technological reserve for innovation incubation. Currently, the medical school is leveraging resources from the innovation ecosystem, including the National University of Singapore’s startup incubator, technology transfer center, and commercialization platforms, to facilitate the translation of innovative projects.

In 2005, the Duke-NUS Medical School jointly launched the “Duke-NUS Healthcare Innovation Programme (DHIP)” and engaged in interdisciplinary collaboration with partners such as SingHealth to establish an end-to-end pathway from technology translation to industrial implementation, thereby fostering technological innovation and the commercialization of research outcomes in the medical field.

Anhui Hanxin Zhihu Technology, established in 2023, was co-founded by USTC alumnus Guo Dagang together with several professors from the Duke-NUS Medical School, focusing on the research and development of products for early screening of high-risk chest pain and intelligent triage.

In August 2024, Duke-NUS Medical School also launched the “Live Ventures” initiative, establishing a S$20 million incubator to provide services such as infrastructure, expert mentorship, funding support, and industry resource matchmaking for innovative projects, thereby enhancing the translation of research from the laboratory to clinical applications.

Another co-founder of the accelerator, 22 Health Ventures, is a venture capital firm focused on early-stage health tech investments. The firm employs a process-driven investment approach, making investment decisions and managing portfolios through standardized, systematic, and normalized procedures. Based in Singapore, the team provides portfolio companies with operational expertise and corporate management guidance, while leveraging its resources within the U.S. healthcare ecosystem to accelerate their entry into the American market. In April 2024, 22 Health Ventures co-led the $7 million seed funding round for Thrixen, a Singapore-based point-of-care diagnostics platform.

Entrepreneurship accelerators are a key initiative for universities to promote the commercialization of research outcomes. First, universities possess abundant academic resources, scientific achievements, and professional faculty, enabling them to provide technical support and guidance for entrepreneurial projects. Second, university research facilities offer entrepreneurs workspace and hardware infrastructure, thereby reducing startup costs. Furthermore, universities’ alumni networks and industry partnerships can bring valuable resources and potential collaboration opportunities to entrepreneurial ventures.

For example, Yale University, in partnership with India’s Cowrks Foundry, launched the “Sustainable Health Initiative,” a six-month interdisciplinary accelerator program targeting early-stage healthcare startups. Each selected company will receive $70,000 in seed funding, mentorship from Yale faculty and alumni, and support from industry experts in India.

Furthermore, FastForward U, the accelerator at Johns Hopkins University in the United States that focuses on cultivating startup projects in the healthcare and medical fields, has accelerated more than 100 entrepreneurial ventures to date. Leveraging its team of expert mentors, abundant industry resources, comprehensive curriculum system, and tight-knit alumni network, the program has supported notable companies such as Illumigym and Cofactor Genomics.

Against the backdrop of the continuous introduction of macro-level policies and supporting documents aimed at encouraging the commercialization of scientific and technological innovations, universities, as a key source of such innovations, have also been continuously improving their internal mechanisms and systems for technology transfer. Many universities in China have launched startup accelerators and achieved remarkable results.

Launched in 2007, Zhejiang University’s “Qiushi Strong Eagle” Startup Accelerator integrates on- and off-campus resources to provide entrepreneurs with a suite of services—including practical training, project incubation, and investment matchmaking—helping numerous startup projects achieve commercialization. Established in 2013, Tsinghua University’s x-lab Startup Accelerator leverages a robust mentor team, entrepreneurial resources, a comprehensive curriculum system, and rigorous project screening mechanisms to offer all-around support services—from idea to market—for startup projects initiated by Tsinghua students and alumni, including coursework, mentorship, and capital matchmaking.

In 2018, the International Innovation Accelerator of Shenzhen University’s Asia-Pacific Innovation College launched a 21-day acceleration program. More than 200 entrepreneurs and innovators from over 50 countries and regions worldwide formed more than 40 teams to carry out activities centered on the theme of “Artificial Intelligence.” In 2019, the Chuangxiang No. 600 Accelerator was established at Shanghai Jiao Tong University National University Science Park. As an off-campus entrepreneurship base for Shanghai Jiao Tong University, it provides integrated, end-to-end services encompassing “infrastructure + technology + services + investment,” serving as a key hub for the commercialization of scientific and technological achievements by faculty, students, and alumni of the university.

In July 2021, the RNA Biomedical Startup Accelerator officially opened applications. Founded by a team of experienced biomedical investors, entrepreneurs, and physician-scientists, it operates facilities in San Francisco, USA, as well as in Shanghai and Hangzhou, China. The program provides early-stage biomedical innovative startups with seed funding, laboratory and office space, and business mentorship for founders.

It is important to note that, due to constraints in resources and institutional mechanisms, university-based startup accelerators may face challenges such as inconsistent mentor quality, misalignment with market demands, unclear project selection criteria, and incomplete curricula, which can limit corporate engagement. When selecting an accelerator, healthcare innovation enterprises should comprehensively evaluate factors including the resources provided, the mentorship team, industry networks, and the degree of alignment with their own projects.